I was also wondering if the trend towards a reversal of fibrosis were good in the most recent mouse studies would that trigger a company interested in pulmonary fibrosis to enter into a partnership to further develop LL in pulmonary fibrosis and possibly MASH. (although joint or separate MASH dialogues and NDA’s could be going on). Thanks for finding and posting this trial. The plot thickens.